Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

Treatment of INS-1 pancreatic b-cells with poly(ADP-ribose) polymerase (PARP) inhibitors attenuates glucose-induced changes in insulin and lipogenic gene expression

L. Olson, K. Linning, D. Jump, D. Ye

Med Sci Monit 2003; 9(1): 51-0 :: ID: 15114

Abstract

Chronic hyperglycemia can alter pancreatic b-cell phenotype by decreasing expression of b-cell specific genes including insulin and GLUT2, while increasing expression of metabolic genes normally not abundantly expressed such as l-pyruvate kinase (l-PK), fatty acid synthase (FAS), acetyl-CoA carboxylase, and lactate dehydrogenase. Treatment of INS-1 pancreatic b-cells with high glucose (16.7 mM) for 48 hrs markedly suppressed insulin promoter activity [1] and induced l-PK promoter activity [1,2]. High glucose also elevated intracellular NAD levels 2-fold compared to control. PARP, an enzyme that uses NAD to poly(ADP-ribosy)late nuclear proteins [3], has been suggested to be involved in ß-cell cytotoxicity, regeneration and differentiation [2,4], and adipocyte differentiation [5]. Thus, we examined the ability of PARP inhibitors – nicotinamide (NAM), 3-aminobenzamide (3-AB), and PD128763 (PD) – to attenuate glucose-mediated changes in insulin and lipogenic gene expression and promoter activities in INS-1 cells. Incubation of INS-1 cells in high glucose for 48 hrs suppressed in suppressed insulin mRNA level >80% and induced l-PK, FAS, and SREBP-1c mRNA levels 4.4-, 12.6-, and 2.7-fold, respectively. Treatment with high glucose concentrations also repressed insulin (–327/+30) promoter activity >80%, and induced l-PK (–4.3 kb/+12) and FAS (–2.4 kb/+16) promoter activity 24- and 21-fold, respectively. Treatment of cells with high glucose plus 10 mM NAM, 10 mM 3-AB, or 500 KM PD, increased insulin mRNA levels and promoter activity 3.4- and 10-fold, respectively. PARP inhibitors also attenuated glucose-mediated induction of l-PK, FAS, and SREBP-1c mRNA levels by 55%, 69%, and 45%, respectively. Moreover, PARP inhibitors attenuated the ability of high glucose to activate l-PK and FAS promoters by 51% and 61%, respectively. These results indicate that PARP inhibitors can attenuate adverse changes in gene expression that occur when b-cells are exposed to elevated glucose concentrations.References: 1.Olson LK, Qian J, Poitout V: Mol Endocrinol, 1998; 12(2): 207-219 2.Newburg E, Qian J, Towle HC, Olson LK: Mol Cell Biochem, 2000; 210: 13-21 3.Virag L, Szabo C: Pharmacol Rev, 2002; 54(3): 375-429 4.Okamoto H, Takasawa S: Diabetes, 2002; 51(suppl. 3): S462-S473 5.Smulson ME, Kang VH, Ntambi JM et al: J Biol Chem, 1995; 270(1): 119-127

Keywords: PARP inhibitors, b-cell phenotype, islet of langerhans, Glucose, insulin gene, lipogenic genes

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750